Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus PROVENTIL HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus PROVENTIL HFA.
ISOETHARINE HYDROCHLORIDE S/F vs PROVENTIL-HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment.
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist